Clinicians, request UNITY Screen kits.
fetal antigens C, c, D, E, Duffy (Fya), Kell (K)
At 10+ weeks in pregnancy, UNITY Screen can look for the presence of specific fetal antigens associated with severe Hemolytic Disease of the Fetus and Newborn (HDFN) including C, c, D, E, Duffy (Fya), and Kell (K) with one blood sample from the pregnancy patient. Results do not rely or depend on obtaining a sample from the partner or undergoing invasive diagnostic testing.
RhD is a more well known red blood cell antigen as Rho (D) immune globulin, or RhoGAM, is available as a preventative treatment to reduce the risks associated with red blood cell antigen incompatibility. There are currently no similar treatments for other red blood cell antigens. Therefore, most of these pregnancies are monitored closely during pregnancy for signs of Hemolytic Disease of the Fetus and Newborn (HDFN).
For Rh-negative patients, UNITY can look for the presence of the fetal RhD antigen to help inform whether or not the pregnancy would benefit from RhoGAM. For alloimmunized patients, UNITY can look for C, c, D, E, Duffy (Fya) or Kell (K) to understand whether or not close monitoring is indicated.
HDFN is caused by incompatible blood types between the pregnant patient and baby. HDFN is a rare disorder that causes red blood cells of a baby to break down too quickly during a pregnancy or shortly after delivery. This can lead to symptoms like an enlarged liver and spleen, anemia, jaundice, and additional complications. Extra monitoring and ultrasounds during pregnancy are recommended for patients at risk.
In addition to the main blood types (A, B, AB, and O), there are other blood groups, or “antigens” attached to red blood cells. When these antigens are present, a person is considered “antigen positive.” If antigens are not present, they are considered “antigen negative.” First pregnancies are typically not at risk for HDFN. In future pregnancies, if the pregnant patient and baby have different antigen types again, the pregnant patient’s immune system can attack the baby’s red blood cells, putting the pregnancy at risk for HDFN.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Streamline management of alloimmunized patients with non-invasive screening for fetal antigens
While rare, Hemolytic Disease of the Fetus and Newborn (HDFN) can be deadly. Screening for C, c, D, E, Duffy (Fya), and Kell (K) antigens can now be added to any UNITY aneuploidy order.
If patient is alloimmunized for C, c, D, E, Duffy (Fya), or Kell (K):
2. ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018 Mar;131(3):e82-e90. doi: 10.1097/AOG.0000000000002528. PMID: 29470342.48(5):941-52. doi: 10.1111/j.1537- 2995.2007.01625.x. Epub 2008 Feb 1. PMID: 18248570. 3. Koelewijn JM, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008 May; 48(5):941-52. doi: 10.1111/j.1537-2995.2007.01625.x. Epub 2008 Feb 1. PMID: 18248570.
NEW! For alloimmunized patients, UNITY now screens for the presence of red blood cell fetal antigens non-invasively and early in pregnancy
UNITY™ sgNIPT has shown > 98.5% sensitivity and >99% specificity in a peer reviewed publication.
It has also shown 100% concordance with newborn screen results in NIH-sponsored clinical study with Baylor College of Medicine and a study with University of Alabama Birmingham.
Single-Molecule Accuracy Powered by QCT™
Using QCT™ molecular counting technology, UNITY™ is able to differentiate homozygous affected fetus (colored bars) from carrier fetus (gray bar). In addition, UNITY™ performs a paternal allele assay to detect a fetus at-risk to be compound heterozygous for CFTR or HBB at >98% detection rate.
Exemplary Readout. Chromosome 21 Ratio: euploid vs trisomy 21
UNITY™ sgNIPT and Aneuploidy + RhD NIPT use synthetic molecules and computational decoding in the bioinformatics stage to reduce the assay amplification noise down to the theoretical limit. Thanks to these proprietary technologies, UNITY™ can uniquely offer reflex sgNIPT and Rh NIPT solutions.
NEW! For alloimmunized patients, UNITY now screens for the presence of RBC fetal antigens associated with severe HDFN
While rare, Hemolytic Disease of the Fetus and Newborn (HDFN) can be deadly. Screening for C, c, D, E, Duffy (Fya), and Kell (K) antigens can now be added to any UNITY aneuploidy order.